OncoSil Medical (ASX:OSL) has announced the appointment of Shelley Steyn as chief financial officer, effective 5 May.
The company said the appointment reflects its ongoing commitment to strengthening its leadership.
OncoSil has developed a cancer treatment device, the OncoSil brachytherapy device, which is a component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer.
Ms Steyn has extensive experience, having more than 17 years in senior accounting, commercial and financial analysis, and audit roles.
She joins OncoSil from Flynn Global Australia and New Zealand, a division of Flynn Group LP, a multibillion-dollar franchise operator in the US. Previous roles include with Sirtex Medical, Deloitte Touche Tohmatsu, and Grant Thornton.
Ms Steyn's appointment follows the resignation of Christian Dal Cin as chief financial officer and company secretary, effective 31 March.
OncoSil CEO Nigel Lange said, "Shelley's demonstrated financial capability and depth of experience across corporate development, capital management, strategic planning and financial controls and compliance will be invaluable to OncoSil as we continue to leverage our strong foundations and grow our business.
"For OncoSil, this decision will help improve financial control, streamline decision-making, and lead to better long-term financial planning.
"We are entering a critical phase as we look to close recruitment on two major clinical trials and prepare for the resubmission of our marketing authorisation application to the Therapeutics Goods Association ("TGA").
"I am delighted to welcome Shelley to our executive team and look forward to working with her to delivering on our strategy and the promise of the OncoSil single-use internal radiation device to treat patients with locally advanced unresectable pancreatic cancer."
